See more : Magseis Fairfield ASA (MSEIS.OL) Income Statement Analysis – Financial Results
Complete financial analysis of Feng Chi Biotech Corp. (6744.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Feng Chi Biotech Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- Movie Games S.A. (2LH.F) Income Statement Analysis – Financial Results
- Halma plc (HLMAF) Income Statement Analysis – Financial Results
- Five Below, Inc. (0IPD.L) Income Statement Analysis – Financial Results
- Birlasoft Limited (BSOFT.NS) Income Statement Analysis – Financial Results
- Sichuan Teway Food Group Co.,Ltd (603317.SS) Income Statement Analysis – Financial Results
Feng Chi Biotech Corp. (6744.TWO)
About Feng Chi Biotech Corp.
Feng Chi Biotech Corp. provides preimplantation genetic testing, prenatal testing, life science, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services. It also distributes various genetic testing technologies and products in oncology. The company is based in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 180.58M | 193.46M | 182.57M | 178.91M | 174.33M |
| Cost of Revenue | 99.86M | 110.02M | 96.46M | 92.98M | 102.08M |
| Gross Profit | 80.72M | 83.44M | 86.11M | 85.92M | 72.25M |
| Gross Profit Ratio | 44.70% | 43.13% | 47.16% | 48.03% | 41.44% |
| Research & Development | 13.10M | 12.09M | 14.19M | 11.91M | 12.95M |
| General & Administrative | 17.86M | 17.60M | 16.90M | 17.29M | 15.85M |
| Selling & Marketing | 25.60M | 26.69M | 28.58M | 28.14M | 23.45M |
| SG&A | 43.46M | 44.29M | 45.48M | 45.43M | 39.20M |
| Other Expenses | -1.03M | 1.54M | 337.00K | -435.00K | 0.00 |
| Operating Expenses | 55.44M | 56.38M | 59.67M | 57.34M | 52.57M |
| Cost & Expenses | 156.42M | 166.39M | 156.13M | 150.32M | 154.65M |
| Interest Income | 3.09M | 1.88M | 1.38M | 1.85M | 2.03M |
| Interest Expense | 325.00K | 58.00K | 98.00K | 167.00K | 17.00K |
| Depreciation & Amortization | 7.21M | 6.31M | 8.80M | 9.89M | 7.49M |
| EBITDA | 34.84M | 36.79M | 36.96M | 39.89M | 27.59M |
| EBITDA Ratio | 19.29% | 19.02% | 20.24% | 22.29% | 15.83% |
| Operating Income | 24.16M | 30.48M | 28.16M | 29.99M | 20.10M |
| Operating Income Ratio | 13.38% | 15.75% | 15.42% | 16.76% | 11.53% |
| Total Other Income/Expenses | 3.14M | 3.35M | 1.62M | 1.24M | 1.59M |
| Income Before Tax | 27.30M | 30.42M | 28.06M | 29.83M | 21.69M |
| Income Before Tax Ratio | 15.12% | 15.72% | 15.37% | 16.67% | 12.44% |
| Income Tax Expense | 4.51M | 5.81M | 4.92M | 4.43M | 4.33M |
| Net Income | 22.79M | 24.61M | 23.14M | 25.39M | 17.36M |
| Net Income Ratio | 12.62% | 12.72% | 12.67% | 14.19% | 9.96% |
| EPS | 1.48 | 1.60 | 1.50 | 1.65 | 1.16 |
| EPS Diluted | 1.47 | 1.60 | 1.50 | 1.64 | 1.16 |
| Weighted Avg Shares Out | 15.40M | 15.38M | 15.40M | 15.40M | 14.95M |
| Weighted Avg Shares Out (Dil) | 15.46M | 15.38M | 15.46M | 15.45M | 14.98M |
Source: https://incomestatements.info
Category: Stock Reports